Proactive Investors - Run By Investors For Investors

Valeant Pharmaceuticals shares slip after US FDA rejects Duobrii lotion for plaque psoriasis

Valeant has requested a meeting with the FDA and is working to overturn its decision
Scientist with a microscope
Valeant shares are down sharply on news of the FDA's denial

The US Food and Drug Administration has failed to approve Valeant Pharmaceuticals International Inc’s (NYSE:VRX) new lotion for the treatment of plaque psoriasis.

In its complete response letter to Valeant laying out its decision, US health regulators posed questions regarding pharmacokinetic data, but did not specify any problems relating to the effectiveness or safety of Duobrii, the lotion.

The Canadian company has requested a meeting with the FDA and is working to resolve the matter as it looks to find a way to bring Duobrii to market.

In cases of plaque psoriasis, the most common type of its kind, the skin is red and inflamed and covered with silvery scales.

Valeant shares fell 12% to close at US$23.54, but the stock is still up roughly 76% over the last year.

View full VRX profile View Profile

Valeant Pharmaceuticals Timeline

Related Articles

harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use